Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss - Vistagen Therapeutics (NAS

Vistagen's Phase 3 fasedienol trial missed its main endpoint, but the company found a severe-patient signal and plans an FDA meeting.

Raccontata dabenzinga.com